TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03821168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of bevacizumab and erythropoietin
Description: injection of bevacizumab and erythropoietin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of bevacizumab
Description: under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
Study: NCT02195986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Cream, 0.01%
Description: Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace® 0.01% cream
Description: Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Cream
Description: Placebo Vaginal Cream ( 1 x 2 g for 7 days)
Study: NCT02802800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Plyometric exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Plyometric exercises
Study: NCT01786928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
Study: NCT01346748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin
Description: Sinvastatin 80 mg per day - 21 days versus placebo
Study: NCT00771810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Once daily subcutaneous injection of 100 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Once daily subcutaneous injection of 300 ug/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily subcutaneous injection of placebo
Study: NCT00449176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER
Description: 50, 100, 150, 200, 250 mg twice daily for 15 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone CR
Description: 10, 20, 30, 40, 50 mg twice daily for 15 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo twice daily for 15 weeks
Study: NCT00623090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational internet site on prostate cancer screening
Description: Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational print booklet
Description: Healthy men between 45-70 receive a copy of our educational print booklet in the mail.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
Study: NCT01900782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: Prefilled syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intervention A
Description: Prefilled syringe.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B
Description: Prefilled syringe.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prefilled syringe to match experimental drug and active comparator.
Study: NCT04357262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: StreaMD
Description: Patients who are randomized to the intervention arm will be signed up for the automated text messaging program. Patients will receive automated text messages related to their surgery during the study period and can also ask questions through the text messages program, where automated messages will be sent based on the questions asked.
Study: NCT01926756

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Straight catheterization
Description: Patient will receive the current standard practice of straight catheterization intraoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No straight catheterization
Description: Patients will not be catheterized which is an experimental change from the current practice at our hospital.
Study: NCT02920827

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal ring
Description: Placebo vaginal ring containing no dapivirine
Study: NCT00837174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat in combination with Bortezomib
Description: Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
Study: NCT03130751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pocket Coach for AYA with Cancer
Description: The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model \[Dr. Joan E. Haase et al\] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
Study: NCT02085148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine (Cellcristin®)
Description: Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine (Cellcristin®)
Description: Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Irinotecan Cell pharm®)
Description: Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Irinotecan Cell pharm®)
Description: Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
Study: NCT02302443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12470
Description: Single dose subcutaneous administration ranging from a very low dose to high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active comparator
Description: Single dose subcutaneous administration of active comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active comparator
Description: Single dose subcutaneous administration of active comparator
Study: NCT03392714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-B(O)AD
Description: rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
Study: NCT03575273

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sniffin' Sticks Odor Identification and Hedonic Scale
Description: This task measures odor identification accuracy and perceived pleasantness of odors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sniffin' Sticks Odor Identification and Hedonic Scale
Description: This task measures odor identification accuracy and perceived pleasantness of odors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sniffin' Sticks Odor Identification and Hedonic Scale
Description: This task measures odor identification accuracy and perceived pleasantness of odors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose Taste Preference Assessment
Description: This task measures participant ratings of sucrose preference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sucrose Taste Preference Assessment
Description: This task measures participant ratings of sucrose preference.
Study: NCT03396718

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation radio(chemo)therapy - Level 1
Description: 54/ 59,4 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation radio(chemo)therapy - Level 2
Description: 48,8/ 55 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radio(chemotherapy)
Description: 60/ 66 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radio(chemotherapy)
Description: 60/ 66 Gy
Study: NCT01350063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)
Description: One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water storage container (Jerry can)
Description: Shallow tubewell water should be stored in 10L container.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study: NCT02598102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Diclofenac for pain relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for comparison
Study: NCT04316858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate
Description: 90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate
Description: 90ml of sodium phosphate will be added to 800ml of solvent( water or zero calorie carbonated drink) and taken in divided doses one day prior to procedure. Whole solution will be finished 3 -4 hours before colonoscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 800 ml of water will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zero calorie carbonated drink
Description: 800 ml of zero calorie diet cola will be added to 90 ml of sodium phosphate to facilitate its intake by the patients preparatory to colonoscopy
Study: NCT03548714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT150
Description: Intervention 1 includes PT150 with alcohol consumption

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beverage
Description: Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
Study: NCT02833402

Intervention type: DEVICE
Intervention: InterStim Therapy
Description: Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
Study: NCT02688608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV once every 3 weeks
Study: NCT01629875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic equivalent of Clostridium Botulinum A Toxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox (Clostridium Botulinum A Toxin)
Study: NCT01250158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver-PILP kit
Description: Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~1. The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~2. The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~3. The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen.
Study: NCT02669680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Study: NCT03075137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External counter pulsation (ECP)
Description: standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
Study: NCT01713712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
Study: NCT00738556

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stents (Cypher and Taxus)
Description: Spot or full length stenting of a coronary lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stents (Cypher and Taxus)
Description: Spot or full length stenting of a coronary lesion
Study: NCT01697007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVIS DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVIS DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIVIS DNA vaccine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zetajet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zetajet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zetajet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax Electroporation
Study: NCT03575273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sucrose Taste Preference Assessment
Description: This task measures participant ratings of sucrose preference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Preferences Task
Description: Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Preferences Task
Description: Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Preferences Task
Description: Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Ratio (PR) Task
Description: In the PR task, the subject is required to make an increasing number of operant responses for each successive reward

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Ratio (PR) Task
Description: In the PR task, the subject is required to make an increasing number of operant responses for each successive reward

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Ratio (PR) Task
Description: In the PR task, the subject is required to make an increasing number of operant responses for each successive reward

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Electrophysiology
Description: To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Electrophysiology
Description: To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
Study: NCT01697007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma Vax Electroporation
Study: NCT03575273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Electrophysiology
Description: To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
Study: NCT01697007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara (MVA-CDMR)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara (MVA-CDMR)
Study: NCT03575273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Meal and Hunger and Satiety Ratings
Description: Participants will receive a standardized meal and complete hunger and satiety ratings.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Meal and Hunger and Satiety Ratings
Description: Participants will receive a standardized meal and complete hunger and satiety ratings.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Meal and Hunger and Satiety Ratings
Description: Participants will receive a standardized meal and complete hunger and satiety ratings.
Study: NCT02044991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
Study: NCT01697007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara (MVA-CDMR)
Study: NCT02222142

Intervention type: DRUG
Intervention: Isoflurane
Description: Comparison between isoflurane and propofol, Retrospective study
Study: NCT02896465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral rehydration solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral rehydration solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Study: NCT02044991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: A placebo injection
Study: NCT02954523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: oral every day
Study: NCT02896465

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zinc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breastfeeding
Study: NCT03125083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological dosage from plasma
Description: The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
Study: NCT02971410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies